Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation

Hepatology

Volumn 60, Issue 6, 2014, Pages 2017-2026

  Levitsky, Josh ^a   Baker, Talia B ^a   Jie, Chunfa ^a   Ahya, Shubhada ^a   Levin, Murray ^a   Friedewald, John ^a   Al Saden, Patrice ^a   Salomon, Daniel R ^b   Abecassis, Michael M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CYSTATIN C; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; OSTEOPONTIN; PEPTIDE; TFF3 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE KIDNEY INJURY; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; CONVALESCENCE; FEMALE; HUMAN; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; AGED; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; HUMANS; LIPOCALINS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPONTIN; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECOVERY OF FUNCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84911925603     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27346     Document Type: Article

References (38)

1. Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl 2012;18:539-548.
2. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. 1998. Impact of acure renal failutre in mortality in end-stage liver disease with or without transplantation. Kidney Int 1998;54:518-524.
3. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934-1939.
4. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
5. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 2008;8:2243-2251.
6. Levitsky J, Baker T, Ahya SN, Levin ML, Friedewald J, Gallon L, et al. 2012. Outcomes and native renal recovery following simultaneous liver-kidney transplantation. Am J Transplant 2012;12:2949-2957.
7. Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, et al. 2012. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 2012;12:2901-2908.
8. Nadim MK, Davis CL, Sung R, Kellum JA, Genyk YS. Simultaneous liver-kidney transplantation: a survey of US transplant centers. Am J Transplant 2012;12:3119-3127.
9. Biancofiore G, Pucci L, Cerutti E, Penno G, Pardini E, Esposito M, et al. 2006. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006;12:285-291.
10. Yu Y, Jin H, Holder D, Ozer JS, Villareal S, Shughrue P, et al. Urinary biomarkers trefoil factore 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 2010;28:470-477.
11. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012;57:2362-2370.
12. Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012;57:267-273.
13. Levitsky J, Salomon DR, Abecassis M, Langfelder P, Horvath S, Friedewald J, et al. Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am J Transplant 2011;11:1972-1978.
14. Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R, Feiner J. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009;15:1852-1860.
15. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
16. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.
17. O'Riordan A, Johnston O, McMorrow T, Wynne K, Maguire P, Hegarty JE, et al. Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics Clin Appl 2008;2:1338-1348.
18. Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R, Feiner J. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009;15:1852-1860.
19. Wagener G, Minhaz M, Mattis FA, Kim M, Emond JC, Lee HT. Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant 2011;26:1717-1723.
20. Basile, D.P., Fredrich, K., Alausa, M., Vio, C.P., Liang, M., Rieder, M.R., et al. Identification of persistently altered gene expression in the kidney after functional recovery from ischemic acute renal failure. Am J Physiol Renal Physiol 2005;288:F953-F963.
21. Hampel DJ, Sansome C, Romanov VI, Kowalski AJ, Denhardt DT, Goligorsky MS. Osteopontin traffic in hypoxic renal epithelial cells. Nephron Exp Nephrol 2003;94:e66-e76.
22. Iguchi S, Nishi S, Ikegame M, Hoshi K, Yoshizawa T, Kawashima H, et al. Expression of osteopontin in cisplatin-induced tubular injury. Nephron Exp Nephrol 2004;97:e96-e105.
23. Rouse RL, Zhang J, Stewart SR, Rosenzweig BA, Espandiari P, Sadrieh NK. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney Int 2011;79:1186-1197.
24. Lorenzen JM, Hafer C, Faulhaber-Walter R, Kumpers P, Kielstein JT, Haller H, Fliser D. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2011;26:531-537.
25. O'Brien LE, Tang K, Kats ES, Schutz-Geschwender A, Lipschutz JH, Mostov KE. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell 2004;7:21-32.
26. Miya M, Maeshima A, Mishima K, Sakurai N, Ikeuchi H, Kuroiwa T, et al. Enhancement of in vitro human tubulogenesis by endothelial cell-derived factors: implications for in vivo tubular regeneration after injury. Am J Physiol Renal Physiol 2011;301:F387-F395.
27. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292:F905-F911.
28. Basile DP, Martin DR, Hammerman MR. Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am J Physiol 1998;275:F894-F903.
29. Kusaka M, Kuroyanagi Y, Ichino M, Sasaki H, Maruyama T, Hayakawa K, et al. Serum tissue inhibitor of metalloproteinases 1 (TIMP-1) predicts organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant 2010;19:723-729.
30. Sharma P, Goodrich NP, Zhang M, Guidinger MK, Schaubel DE, Merion RM. Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol 2013;8:1135-1142.
31. Lorena D, Darby IA, Gadeau AP, Leen LL, Rittling S, Porto LC, et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol 2006;44:383-390.
32. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012;7:e35612.
33. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
34. Dechene A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, et al. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology 2010;52:1008-1016.
35. Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 2012;7:e38629.
36. Pascaretti-Grizon F, Gaudin-Audrain C, Gallois Y, Retaillaud-Gaborit N, Basle MF, Chappard D. Osteopontin is an argentophilic protein in the bone matrix and in cells of kidney convoluted tubules. Morphologie 2007;91:180-185.
37. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. 1999. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999;104:1191-1197.
38. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118:1657-1668.